International Journal of Biological Sciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2025-05-01 ms3000001161611445 来自广东省

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：机制;生物
经验分享：Received 2024-12-4
Major revision (more positive) 2025-1-20
Received 2025-4-1
Conditional acceptance 2025-4-16

6 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2025-02-02 1891e859aem

偏重的研究方向：分子生物学;医学;肿瘤
经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28

18 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2024-04-06 ms7000001898488025 来自北京

偏重的研究方向：分子生物学
经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀#投稿经验#

58 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2025-03-04 shuaiydemo 来自北京

replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀

13 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2024-02-22 Jojo 来自北京

replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？

55 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2024-11-19 缅怀21世纪来自四川省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？

50 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2025-04-07 阿云龙来自江苏省

两天了还是received状态，正常吗？到编辑手里状态会更新吗

9 0

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2023-03-06 541350208 来自重庆

2.8号投稿，审稿中

97 25

展开25条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2024-11-27 541350208 来自重庆

即时影响因子8.2，预测9.8，今年能一区吗？

26 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2263050, encodeId=beb722630500b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：机制;生物 经验分享：Received 2024-12-4 Major revision (more positive) 2025-1-20 Received 2025-4-1 Conditional acceptance 2025-4-16 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0775546096, createdName=ms3000001161611445, createdTime=Thu May 01 16:01:54 CST 2025, time=2025-05-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2250270, encodeId=88ad22502e048, content=偏重的研究方向：分子生物学;医学;肿瘤 经验分享：Received 2025-1-25 from IP Conditional acceptance 2025-2-2 Received 2024-12-6 from IP Major revision (more positive) 2025-1-10 Received 2024-8-25 from IP Major revision (more positive) 2024-9-28, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Sun Feb 02 08:53:43 CST 2025, time=2025-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197183, encodeId=e957219e183e3, content=偏重的研究方向：分子生物学 经验分享：请问各位大佬，大修今天返回，就在投稿这个页面，急求上传补充材料的地方，或者说是上传wb原始数据的地方在哪里呀，感谢好心人救救我呀<a href='/topic/show?id=59945501884' target=_blank style='color:#2F92EE;'>#投稿经验#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=55018, encryptionId=59945501884, topicName=投稿经验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=365b5687069, createdName=ms7000001898488025, createdTime=Sat Apr 06 20:43:47 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254589, encodeId=d307225458996, content=replace消失，一直显示in review，这个状态和under review是一个意思吗？大家显示的是啥呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/30/20a654dc37d358bb1110b34f089636c9.jpg, createdBy=71081986125, createdName=shuaiydemo, createdTime=Tue Mar 04 22:48:05 CST 2025, time=2025-03-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188800, encodeId=91e62188800d0, content=replace 消失，状态从投稿完到现在一直是Received from IP This manuscript is under review. 求助大家这是送外审了吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Thu Feb 22 23:55:42 CST 2024, time=2024-02-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2259519, encodeId=bf87225951994, content=两天了还是received状态，正常吗？到编辑手里状态会更新吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e14b5438201, createdName=阿云龙, createdTime=Mon Apr 07 22:12:54 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2117981, encodeId=f6a1211e981d8, content=2.8号投稿，审稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Mon Mar 06 19:49:41 CST 2023, time=2023-03-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=)]

2022-02-23 悬崖听风007

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫
经验分享：Received 2021-12-16 from IP
Minor revision 2022-2-8
Received 2022-2-17 from IP
Final accept 2022-2-22
Pre-publish-fee 2022-2-22
投稿到接受2个月零几天，效率杠杠的。感恩。

146 20

展开20条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务